Medscape - "Alemtuzumab Benefits Hard-to-Treat MS Patients"

New York, NY
 – June 2, 2013 /Press Release/  –– 

Alemtuzumab (Lemtrada, Genzyme Corporation/sanofi-aventis) benefits the hardest-to-treat multiple sclerosis (MS) patients, even when the efficacy bar is set at the high possible level, a new study suggests. In CARE-MS II, for example, the relapse rate was reduced by 49 percent, and disability by 42 percent, compared with interferon, and magnetic resonance imaging (MRI) numbers were 'favorable," said Stephen Krieger, Assistant Professor of Neurology, The Mount Sinai Medical Center, who presented the results in Orlando at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). Learn more (subscription required)